Maxon One Explodes with Exciting New Features and Workflow Improvements
9.11.2022 20:00:00 EET | Business Wire | Press release
Maxon, developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced several updates to the company’s Maxon One product line. The November 2022 release features a blazingly hot new feature for Cinema 4D - Pyro. Pyro allows artists to create fire, smoke and explosions - easily simulated using GPU or CPU. Other Cinema 4D features include an integrated Redshift Camera and Radial Symmetry for modeling. Forger expands its professional modeling functions by adding Cinema 4D's advanced Symmetry capabilities. The latest release of VFX enhances Real Lens Flares with more natural elements, adding Schmutz and Diffraction effects to the optical simulation. The latest version of Trapcode offers an interactive and updated user interface for Particular's curves and color gradients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005139/en/
Maxon One Receives New Features and Improvements in November Release: Cinema 4D receives new Pyro tool, Trapcode Particular shines in an updated UI, the first full version of Real Lens Flares is released and Forger expands professional modeling capabilities. (Graphic: Business Wire)
Cinema 4D 2023.1: Cinema 4D introduces Pyro! for creating fire, smoke and explosions. Seamless integration in Cinema 4D’s Unified Simulation System, means Cloth and Soft Bodies can be set ablaze and fan the flames. A newly integrated RedShift Camera brings intuitive physical camera controls and Redshift effect settings. New Radial Symmetry modeling allows the interactive modeling of anything round by defining a number of slices and offset. And, many more workflow enhancements are included.
Forger: Forger continues to add the comprehensive modeling capabilities of Cinema 4D to iPad with the addition of Symmetry modeling, bringing desktop power and workflows to mobile flexibility.
VFX: The latest version of VFX introduces the first full version of Real Lens Flares adding Schmutz and Diffraction to make lens look grimy and add rippling effects to each lens flare reflection element. Dozens of presents as well as base lens prescriptions have also been added.
Trapcode: Trapcode 2023.1 offers a completely refreshed and upgraded user interface for the Particular curves and color gradients as well as new emitter block presets for Form behaviors and improved performance.
Capsules: Maxon continues to deliver valuable Capsule assets that subscribers can use as a creative kickstart. Artists can now easily compose a product shot with the new Backdrop Primitive, and a new Square Star Spline and FUI Ring Spline create a variety of crosshair and reticule shapes for FUI graphics.
Cineware for Unreal: An updated Cineware for Unreal integration now supports Cinema 4D 2023.1 and Unreal Engine 5.0.3. Easily import C4D files into Unreal and make changes without leaving the engine environment.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush, the industry-standard digital sculpting and painting solution.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005139/en/
Contact information
Press
Chloe Larby
Grithaus Agency
chloe@grithaus.agency
+44 7454 012045
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom